Guidant's Start-Up Mentality
Executive Summary
Over the past four years, Guidant has been one of the most impressive performers among a group of high-flying big-cap device giants. But even as it wrestles with the usual problems of managing large businesses, in its penchant for self-invention and relentless pursuit of new technology, Guidant behaves more like the collection of start-ups its once was.
You may also be interested in...
Lilly Tries to Buy Time
Facing a steep patent cliff and a dearth of late-stage drugs, Lilly is slashing expenses, reorganizing R&D, and hoping to attract investors to share the risks and rewards of pipeline development. Will these moves be enough?
Lilly Tries to Buy Time
Facing a steep patent cliff and a dearth of late-stage drugs, Lilly is slashing expenses, reorganizing R&D, and hoping to attract investors to share the risks and rewards of pipeline development. Will these moves be enough?
From Guidant to Abbott: An Interview with John Capek
Some industry executives argue that the real winner in the battle between Johnson & Johnson and Boston Scientific for Guidant was Abbott, who came away with a bulked up interventional cardiology business and what promises to be the next big winner in drug-eluting stents. John Capek played a major role in growing Guidant's business and, post-sale, helped guide a successful integration within Abbott. Now, he's running all of Abbott's medical device businesses.